Trust Company of Vermont’s iShares Biotechnology ETF IBB Stock Holding History

Trust Company of Vermont’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$43.7K	Buy	+230	New	+$39.5K	﹤0.01%	634
2025 Q4	$26.2K	Hold	155	–	–	﹤0.01%	697
2025 Q3	$22.4K	Buy	+155	New	+$21.2K	﹤0.01%	721
2024 Q4	–	Sell	-569	Closed	-$82.8K	–	1084
2024 Q3	$82.8K	Sell	569 -100	-15%	-$14.5K	﹤0.01%	436
2024 Q2	$91.8K	Hold	669	–	–	0.01%	413
2024 Q1	$91.8K	Buy	669 +344	+106%	+$47K	0.01%	399
2023 Q4	$44.2K	Hold	325	–	–	﹤0.01%	444
2023 Q3	$39.7K	Hold	325	–	–	﹤0.01%	475
2023 Q2	$41.3K	Sell	325 -200	-38%	-$26K	﹤0.01%	503
2023 Q1	$67.8K	Sell	525 -102	-16%	-$13.4K	﹤0.01%	447
2022 Q4	$82.3K	Buy	627 +102	+19%	+$13.2K	0.01%	414
2022 Q3	$61K	Hold	525	–	–	﹤0.01%	459
2022 Q2	$62K	Buy	+525	New	+$62.3K	﹤0.01%	450
2022 Q1	–	Sell	-745	Closed	-$114K	–	511
2021 Q4	$114K	Buy	+745	New	+$115K	0.01%	379
2021 Q3	–	Sell	-745	Closed	-$122K	–	496
2021 Q2	$122K	Sell	745 -140	-16%	-$21.6K	0.01%	367
2021 Q1	$133K	Buy	885 +360	+69%	+$57.2K	0.01%	345
2020 Q4	$80K	Hold	525	–	–	0.01%	403
2020 Q3	$71K	Hold	525	–	–	0.01%	404
2020 Q2	$72K	Buy	525 +225	+75%	+$28.7K	0.01%	398
2020 Q1	$32K	Hold	300	–	–	﹤0.01%	497
2019 Q4	$36K	Hold	300	–	–	﹤0.01%	519
2019 Q3	$30K	Hold	300	–	–	﹤0.01%	561
2019 Q2	$33K	Hold	300	–	–	﹤0.01%	537
2019 Q1	$34K	Hold	300	–	–	﹤0.01%	528
2018 Q4	$29K	Hold	300	–	–	﹤0.01%	549
2018 Q3	$37K	Hold	300	–	–	﹤0.01%	564
2018 Q2	$33K	Sell	300 -939	-76%	-$100K	﹤0.01%	594
2018 Q1	$132K	Buy	1,239 +384	+45%	+$42.6K	0.01%	362
2017 Q4	$91K	Hold	855	–	–	0.01%	411
2017 Q3	$95K	Hold	855	–	–	0.01%	409
2017 Q2	$88K	Hold	855	–	–	0.01%	426
2017 Q1	$83K	Hold	855	–	–	0.01%	426
2016 Q4	$76K	Hold	855	–	–	0.01%	425
2016 Q3	$83K	Hold	855	–	–	0.01%	369
2016 Q2	$74K	Hold	855	–	–	0.01%	352
2016 Q1	$74K	Hold	855	–	–	0.01%	347
2015 Q4	$96K	Buy	855 +90	+12%	+$9.77K	0.01%	319
2015 Q3	$77K	Buy	765 +375	+96%	+$45K	0.01%	338
2015 Q2	$48K	Buy	390 +30	+8%	+$3.59K	0.01%	408
2015 Q1	$41K	Buy	360 +30	+9%	+$3.31K	0.01%	428
2014 Q4	$33K	Buy	330 +30	+10%	+$2.92K	﹤0.01%	465
2014 Q3	$27K	Hold	300	–	–	﹤0.01%	494
2014 Q2	$26K	Hold	300	–	–	﹤0.01%	479
2014 Q1	$24K	Buy	+300	New	+$25K	﹤0.01%	486

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.9% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Trust Company of Vermont's IBB Position: Q2 2026 in Review

Trust Company of Vermont opened a new position in iShares Biotechnology ETF (IBB) in Q2 2026: 230 shares worth $43.7K. The stake represents ﹤0.01% of the portfolio and ranks #634 among its holdings. This is a return to the name: Trust Company of Vermont previously reported a position in IBB as recently as Q4 2025.

Trust Company of Vermont first reported a position in IBB in Q1 2014 and has held it in 44 quarters since. The position peaked at $133K in Q1 2021. 960 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

Trust Company of Vermont held 230 shares of iShares Biotechnology ETF worth $43.7K as of Q2 2026.
iShares Biotechnology ETF was a new Trust Company of Vermont position in Q2 2026.
iShares Biotechnology ETF made up ﹤0.01% of Trust Company of Vermont's portfolio in Q2 2026, its #634 holding.
Trust Company of Vermont first reported a position in iShares Biotechnology ETF in Q1 2014 and has held it in 44 quarters since.
Trust Company of Vermont's iShares Biotechnology ETF position peaked at $133K in Q1 2021.
960 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Trust Company of Vermont's 13F filing for Q2 2026, filed 7 Aug 2026.